• Product NameForetinib (GSK1363089)
• Brief DescriptionInhibitors
• Purification99.80%
• Biological ActivityForetinib (GSK1363089) is an ATP-competitive inhibitor of HGFR and VEGFR, mostly for Met and KDR with IC50 of 0.4 nM and 0.9 nM. Less potent against Ron, Flt-1/3/4, Kit, PDGFRα/β and Tie-2, and little activity to FGFR1 and EGFR. Phase 2.
• Target Namec-Met/HGFR inhibitor; Tie-2 inhibitor; VEGFR inhibitor
• CAS No. 849217-64-7
• Calculated MW 632.65
• Formulation C34H34F2N4O6
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:COC1=CC2=C(OC3=C(F)C=C(C=C3)N(C(=O)C3(CC3)C(N)=O)C3=CC=C(F)C=C3)C=CN=C2C=C1OCCCN1CCOCC1
  Pathways:Angiogenesis; Tyrosine Kinase/Adaptors
  Receptor:Met; RON; Tie-2; VEGFR2?(KDR); VEGFR3/FLT4
  Boling pt:
  Melting pt:
  Solubility:DMSO: 127 mg/mL (200.74 mM)
  Appearance:White Powder
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Qian F, et al. Y Res, 2009, 69(20), 8009-8016.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting